Thrombosis Drug Market - Global Industry Analysis

Table Of Content

Methodology

Free Analysis

Thrombosis is a condition in which blood gets a clot in the blood vessel, which leads to the obstruction of blood flow in the circulatory system and it may travel to the other body parts. Thrombosis drugs are those drugs which are used to treat the blood clots formed in the blood arteries and veins. These drugs generally include anticoagulant drugs and thrombin inhibitor drugs which dilute the blood and dissolve the blood clot in the arteries and veins and also reduce the chances of embolism. These drugs are available in the form of a capsule, tablet, and injection. As per the Center for Disease Control and Prevention report 2015, the exact number of people diagnosed with deep vein thrombosis or pulmonary embolism is not known, although it is estimated that 900,000 people could be affected (1 to 2 per 1,000) each year in the United States.

The major factors driving the growth of thrombosis drug market are increased the prevalence of thrombosis coupled with the availability of new products. As per the International Society on Thrombosis and Haemostasis report every year, there are approximately 10 million cases of venous thromboembolism recorded worldwide. There are various companies which are constantly working for the development of various new and effective drugs which is expected to provide better results as compared to conventional drugs. The companies have research and development department which helps in the development of these drugs and further launch of new drugs in the area of treatment are further expected to promote the growth of thrombosis treatment market. Moreover, unmet needs of people and significant technological advancements in the healthcare sectors and new product launches are expected to fuel the growth of thrombosis drug market. However, increased use of generic drugs is expected to hamper the growth of thrombosis drug market over the forecast period.

Thrombosis drug market is segmented on the basis of drug class such as Factor Xa Inhibitor, Low Molecular Weight Heparin, and P2Y12 Platelet Inhibitor. Factor Xa Inhibitor segment is expected to dominate the thrombosis drug market over the forecast period. Based on the indication, the thrombosis drug market is segmented into pulmonary embolism, atrial fibrillation, and deep vein thrombosis. Pulmonary embolism is expected to dominate the thrombosis drug market in the near future. Based on the distribution channel, the thrombosis drug market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Over the forecast period, hospital pharmacies are expected to dominate the thrombosis drug market.

Based on the region, the global thrombosis drug market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is expected to dominate the thrombosis drug market in the near future which is closely followed by Europe owing to the various technological advancement and increased prevalence of thrombosis. The Asia Pacific is expected to expand moderately over the forecast period. Latin America and the Middle East & Africa are expected to develop considerably. 

Some of the major key players of thrombosis drug market include GlaxoSmithKline Plc., Aspen Pharmacare Holdings Limited, Johnson & Johnson, Sanofi, AstraZeneca Plc, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Baxter International Inc., and Pfizer, Inc., among others.